A Study of Infliximab (Remicade) in Patients With Ankylosing Spondylitis.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00207701|
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : May 17, 2011
|Condition or disease||Intervention/treatment||Phase|
|Ankylosing Spondylitis||Drug: infliximab||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||279 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Double-blind Trial of the Efficacy of REMICADE (Infliximab) Compared With Placebo in Subjects With Ankylosing Spondylitis Receiving Standard Anti-inflammatory Drug Therapy|
|Study Start Date :||September 2002|
|Study Completion Date :||February 2005|
U.S. FDA Resources
- The primary endpoint of this study was the proportion of subjects who achieved an ASAS 20 response at week 24.
- The change from baseline in BASFI at week 24, the proportion of subjects who achieved an AS major clinical response at week 24, and the change from baseline in the physical component summary score of the SF-36 at week 24
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00207701
|Study Director:||Centocor, Inc. Clinical Trial||Centocor, Inc.|